Matinas Biopharma Holdings Inc Stock News

Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids an

Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial

Matinas Biopharma Holdings, Inc. (MTNB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in rai

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Representative Jerry Jabbour - Chief Exe

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the s

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of n

BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids a

BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology BridgeBio Pharma Inc 

Matinas BioPharma Holdings Inc. (NYSE:MTNB ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Developmen

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas’ proprietary LNC platform technology –

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of